Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed cancer ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

Johnson & Johnson is a dividend king stock whose strong product line and consistency has earned it a listing on the Dow Jones ...

We recently published a list of 13 Best Cheap Stocks to Invest in for Beginners. In this article, we are going to take a look ...

Johnson & Johnson (NYSE:JNJ) receives a stock grade upgrade to “Buy” by Johnson Rice. The company is scheduled to participate ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NorthRock Partners made a bold move by increasing its stake in Johnson & Johnson by 160.2%, adding 25,665 shares worth $6 ...

Johnson & Johnson MedTech, a global leader in breast aesthetics and reconstruction1, today announced the U.S. launch of MENTOR™ MemoryGel™ Enhance Breast Implants, filling a critical gap in ...

As of March 31, 2025, LAVA had cash, cash equivalents, and short-term investments of $66.6 million, compared to cash, cash equivalents, and short-term investments of $76.6 million as of December 31, ...

Johnson & Johnson (J&J) has announced that its bladder cancer therapy Balversa (erdafitinib) has been accepted by the ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Johnson & Johnson (NYSE:JNJ) from ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.